What does ONL Therapeutics do?

ONL Therapeutics is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, founded in 2011. The company is dedicated to developing innovative neuroprotective therapies aimed at preserving vision in patients with retinal diseases. Its technology focuses on protecting retinal cells from Fas-mediated cell death, offering a new approach to treating various blinding conditions. The lead product candidate, ONL1204 Ophthalmic Solution, is currently in clinical development and targets a range of retinal diseases, including retinal detachment, glaucoma, age-related macular degeneration, and inherited retinal diseases. ONL Therapeutics has successfully raised $132.6 million in funding to support its advancements, with notable investors including Visionary Ventures and Novartis Venture Fund.